In our study, the breast cancer-associated mortality of BRCA2 carriers with ER-positive breast cancer was higher than expected in a patient group, where adjuvant chemotherapy was less-frequently used, but lower than expected in the high-risk patient group where adjuvant chemotherapy was used more often (Supplementary Table 4). The gene discussed is BRCA2; the disease is breast cancer.